ArticleInternational wound journal2021
An evaluation of the bacteriostatic effect of platelet-rich plasma.
Article in International wound journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- The Effectiveness, Safety and Cost-Effectiveness of Platelet-Rich Plasma and Platelet-Rich Fibrin in the Treatment of Venous Leg Ulcers: A Systematic Review and Meta-Analysis.International wound journal · 2026Pooled it
- Efficacy and safety of allogeneic platelet-rich plasma in chronic wound treatment: a meta-analysis of randomized controlled trials.Scientific reports · 2024Pooled it
- Platelet-rich plasma for pilonidal disease: a systematic review.The Journal of international medical research · 2023Pooled it
- Platelet-rich therapies in cutaneous and mucocutaneous disorders characterized by inflammatory tissue responses: mechanistic insights and clinical evidence.Frontiers in medicine · 2026Review
- Antibacterial and antibiofilm activity of platelet-rich plasma under different activation conditions against multidrug-resistant MRSA isolated from human skin abscesses.BMC biotechnology · 2025Article
- In vitro antimicrobial activity of non-traditional therapies for infectious endometritis in mares.Equine veterinary journal · 2025Article
- Platelet-rich plasma as a potential antimicrobial agent against multidrug-resistant bacteria in diabetic foot infections.Scientific reports · 2025Article
- Effect of platelet-rich plasma and platelet-rich fibrin on healing of burn wound with dual-species biofilm.The Kaohsiung journal of medical sciences · 2025Article
- Platelet concentrates in diabetic foot ulcers: A comparative review of PRP, PRF, and CGF with case insights.Regenerative therapy · 2025Article
- Plasma and complement proteins are essential for the antimicrobial activity of canine platelet lysate.Frontiers in veterinary science · 2025Article
- Non-oral pharmacological interventions in the management of herpes zoster-related pain: a review of current research.Frontiers in pain research (Lausanne, Switzerland) · 2024Review
- Antimicrobial Effects of Platelet-Rich Plasma and Platelet-Rich Fibrin: A Scoping Review.Cureus · 2023Article
- Surface Environment and Energy Density Effects on the Detection and Disinfection of Microorganisms Using a Portable Instrument.Sensors (Basel, Switzerland) · 2023Article
- PRP and PRF-Subgroups and Divisions When Used in Dentistry.Journal of personalized medicine · 2021Review
- An evaluation of the bacteriostatic effect of platelet-rich plasma.International wound journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic wounds are a considerable health burden with high morbidity and poor rates of healing. Colonisation of chronic wounds by bacteria can be a significant factor in their poor healing rate. These bacteria can develop antibiotic resistance over time and can lead to wound infections, systemic illness, and occasionally amputation. When a large number of micro-organisms colonise wounds, they can lead to biofilm formation, which are self-perpetuating colonies of bacteria closed within an extracellular matrix, which are poorly penetrated by antibiotics. Platelet-rich plasma (PRP) is an autologous blood product rich in growth factors and cytokines that are involved in an inflammatory response. PRP can be injected or applied to a wound as a topical gel, and there is some interest regarding its antimicrobial properties and whether this can improve wound healing. This study aimed to evaluate the in vitro bacteriostatic effect of PRP. PRP was collected from healthy volunteers and processed into two preparations: activated PRP-activated with calcium chloride and ethanol; inactivated PRP. The activity of each preparation against Staphylococcus aureus and Staphylococcus epidermis was evaluated against a control by three experiments: bacterial kill assay to assess planktonic bacterial growth; plate colony assay to assess bacterial colony growth; and colony biofilm assay to assess biofilm growth. Compared with control, both preparations of PRP significantly inhibited growth of planktonic S aureus and S epidermis. Activated PRP reduced planktonic bacterial concentration more than inactivated PRP in both bacteria. Both PRP preparations significantly reduced bacterial colony counts for both bacteria when compared with control; however, there was no difference between the two. There was no difference found between biofilm growth in either PRP against control or against the other preparation. This study demonstrates that PRP does have an inhibitory effect on the growth of common wound pathogens. Activation may be an important factor in increasing the antimicrobial effect of PRP. However, we did not find evidence of an effect against more complex bacterial colonies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.